Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report

The identification of ERBB2 (HER2) alteration in some solid tumors has become critically important due to the actionable events predictive of response to anti-HER2 therapy. However, the efficacy of ERBB2 mutated hilar cholangiocarcinoma (hCCA) against ERBB2 is rarely reported. Here we report a 76-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Daobing, Zhao, Xiaofei, Di, Liang, Lou, Luyan, Song, Yanfang, Zhang, Yanrui, Liu, Huanhuan, Li, Guangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300950/
https://www.ncbi.nlm.nih.gov/pubmed/35875132
http://dx.doi.org/10.3389/fonc.2022.918297
_version_ 1784751325512204288
author Zeng, Daobing
Zhao, Xiaofei
Di, Liang
Lou, Luyan
Song, Yanfang
Zhang, Yanrui
Liu, Huanhuan
Li, Guangming
author_facet Zeng, Daobing
Zhao, Xiaofei
Di, Liang
Lou, Luyan
Song, Yanfang
Zhang, Yanrui
Liu, Huanhuan
Li, Guangming
author_sort Zeng, Daobing
collection PubMed
description The identification of ERBB2 (HER2) alteration in some solid tumors has become critically important due to the actionable events predictive of response to anti-HER2 therapy. However, the efficacy of ERBB2 mutated hilar cholangiocarcinoma (hCCA) against ERBB2 is rarely reported. Here we report a 76-year-old female diagnosed with hCCA complicated by liver metastases after radical resection. The next-generation sequencing assay showed that the tumor had an ERBB2 mutation. Then, the patient was treated with trastuzumab plus capecitabine. After 2 months of treatment, she had a partial response. Until now, the patient is still alive. This study has shown the potential of trastuzumab combined with capecitabine as an effective treatment for hilar cholangiocarcinoma complicated by liver metastases harboring ERBB2 alterations.
format Online
Article
Text
id pubmed-9300950
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93009502022-07-22 Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report Zeng, Daobing Zhao, Xiaofei Di, Liang Lou, Luyan Song, Yanfang Zhang, Yanrui Liu, Huanhuan Li, Guangming Front Oncol Oncology The identification of ERBB2 (HER2) alteration in some solid tumors has become critically important due to the actionable events predictive of response to anti-HER2 therapy. However, the efficacy of ERBB2 mutated hilar cholangiocarcinoma (hCCA) against ERBB2 is rarely reported. Here we report a 76-year-old female diagnosed with hCCA complicated by liver metastases after radical resection. The next-generation sequencing assay showed that the tumor had an ERBB2 mutation. Then, the patient was treated with trastuzumab plus capecitabine. After 2 months of treatment, she had a partial response. Until now, the patient is still alive. This study has shown the potential of trastuzumab combined with capecitabine as an effective treatment for hilar cholangiocarcinoma complicated by liver metastases harboring ERBB2 alterations. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9300950/ /pubmed/35875132 http://dx.doi.org/10.3389/fonc.2022.918297 Text en Copyright © 2022 Zeng, Zhao, Di, Lou, Song, Zhang, Liu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zeng, Daobing
Zhao, Xiaofei
Di, Liang
Lou, Luyan
Song, Yanfang
Zhang, Yanrui
Liu, Huanhuan
Li, Guangming
Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report
title Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report
title_full Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report
title_fullStr Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report
title_full_unstemmed Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report
title_short Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report
title_sort effectiveness of trastuzumab combined with capecitabine treatment in a patient with hilar cholangiocarcinoma complicated by liver metastases with an erbb2-activating mutation: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300950/
https://www.ncbi.nlm.nih.gov/pubmed/35875132
http://dx.doi.org/10.3389/fonc.2022.918297
work_keys_str_mv AT zengdaobing effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport
AT zhaoxiaofei effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport
AT diliang effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport
AT louluyan effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport
AT songyanfang effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport
AT zhangyanrui effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport
AT liuhuanhuan effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport
AT liguangming effectivenessoftrastuzumabcombinedwithcapecitabinetreatmentinapatientwithhilarcholangiocarcinomacomplicatedbylivermetastaseswithanerbb2activatingmutationacasereport

Ejemplares similares